Teva announced the approval of Raloxifene Tablets, the generic version of Eli Lilly‘s Evista.

Raloxifene is a selective estrogen receptor modulator (SERM) indicated for the prevention and treatment of osteoporosis in postmenopausal women, and for the reduction in risk of invasive breast cancer in postmenopausal women that have osteoporosis and/or are at high risk for invasive breast cancer.  The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism).

RELATED: Musculoskeletal Disorders Resource Center

Raloxifene Tablets will be available in a 60mg dosage strength. Teva will begin shipping the product within the next 30 days.

For more information call (888) 838-2872 or visit